{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:18:05Z","timestamp":1792145885505,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.schres.2017.05.040","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T21:15:44Z","timestamp":1496870144000},"page":"226-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-3250","authenticated-orcid":false,"given":"Amir","family":"Krivoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldar","family":"Hochman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra-Verena","family":"Sendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Vilner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7278-528X","authenticated-orcid":false,"given":"Mirjana","family":"Selakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Taler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2017.05.040_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00210-006-0115-9","article-title":"Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex","volume":"374","author":"Abekawa","year":"2006","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.schres.2017.05.040_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2014.12.069","article-title":"Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis","volume":"226","author":"Ahmed","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/sji.12158","article-title":"Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment","volume":"80","author":"Ajami","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.schres.2017.05.040_bb0020","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0006-3223(88)90052-2","article-title":"Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers","volume":"23","author":"Alfredsson","year":"1988","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0025","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.neuropharm.2011.01.008","article-title":"Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats","volume":"62","author":"Amitai","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2017.05.040_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0079-6123(03)46011-1","article-title":"Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia","volume":"146","author":"Angelucci","year":"2004","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.schbul.a006901","article-title":"When symptoms persist: clozapine augmentation strategies","volume":"27","author":"Buckley","year":"2001","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.05.040_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eurpsy.2015.12.001","article-title":"BDNF Val66Met and clinical response to antipsychotic drugs: a systematic review and meta-analysis","volume":"33","author":"Cargnin","year":"2016","journal-title":"Eur. Psychiatry."},{"key":"10.1016\/j.schres.2017.05.040_bb0045","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.psychres.2011.01.011","article-title":"Effects of antipsychotics on the serum BDNF levels in schizophrenia","volume":"189","author":"Chen","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0006-8993(02)03215-8","article-title":"Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration","volume":"954","author":"Chlan-Fourney","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1126\/science.275.5301.838","article-title":"Dopaminergic neurons protected from degeneration by GDNF gene therapy","volume":"275","author":"Choi-Lundberg","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.schres.2017.05.040_bb0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-005-2174-x","article-title":"Predictors and markers of clozapine response","volume":"179","author":"Chung","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2017.05.040_bb0070","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0075","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0080","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2174\/138920112800784961","article-title":"The glutamate hypothesis of schizophrenia: neuroimaging and drug development","volume":"13","author":"Egerton","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.schres.2017.05.040_bb0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/BF01291892","article-title":"Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics","volume":"104","author":"Evins","year":"1997","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.schres.2017.05.040_bb0090","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/schbul\/sbt137","article-title":"Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification","volume":"39","author":"Farooq","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.05.040_bb0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neulet.2007.04.001","article-title":"Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder","volume":"420","author":"Gama","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2017.05.040_bb0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-1177-y","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0110","article-title":"Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia","volume":"18","author":"Goldstein","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2017.05.040_bb0115","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/mp.2010.88","article-title":"Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis","volume":"16","author":"Green","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpsychires.2006.01.005","article-title":"Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics","volume":"41","author":"Grillo","year":"2007","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0125","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jpsychires.2012.03.015","article-title":"Different serine and glycine metabolism in patients with schizophrenia receiving clozapine","volume":"46","author":"Hons","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.bp.113.138578","article-title":"A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic)","volume":"205","author":"Howes","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.mp.4001552","article-title":"Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action","volume":"10","author":"Javitt","year":"2005","journal-title":"Mol. Psychiatry"},{"issue":"Suppl. 9","key":"10.1016\/j.schres.2017.05.040_bb0140","first-page":"35","article-title":"Treatment-resistant schizophrenic patients","volume":"57","author":"Kane","year":"1996","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2017.05.040_bb0145","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0304-3940(02)00529-3","article-title":"Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets","volume":"328","author":"Karege","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2017.05.040_bb0160","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1176\/appi.ajp.2011.11010039","article-title":"The NIMH-CATIE Schizophrenia Study: what did we learn?","volume":"168","author":"Lieberman","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"5111","key":"10.1016\/j.schres.2017.05.040_bb9000","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.schres.2017.05.040_bb0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1471-4159.1977.tb09621.x","article-title":"Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals","volume":"29","author":"McGale","year":"1977","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2017.05.040_bb0170","first-page":"465","article-title":"Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics","volume":"36","author":"Melkersson","year":"2015","journal-title":"Neuro. Endocrinol. Lett."},{"key":"10.1016\/j.schres.2017.05.040_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2014the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2017.05.040_bb0180","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.schres.2017.05.040_bb0185","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2017.05.040_bb0195","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbv151","article-title":"Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive","volume":"42","author":"Mouchlianitis","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.05.040_bb0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neulet.2011.01.039","article-title":"Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation","volume":"491","author":"Pedrini","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2017.05.040_bb0205","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/mp.2015.96","article-title":"Association of serum VEGF levels with prefrontal cortex volume in schizophrenia","volume":"21","author":"Pillai","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"Suppl. 20","key":"10.1016\/j.schres.2017.05.040_bb0210","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0215","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euroneuro.2004.12.005","article-title":"The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia","volume":"15","author":"Shoval","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2017.05.040_bb0220","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.05.040_bb0225","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpsychires.2010.01.002","article-title":"Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response","volume":"44","author":"Souza","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","article-title":"Results of phase 3 of the CATIE schizophrenia trial","volume":"107","author":"Stroup","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0235","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145705005237","article-title":"Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia","volume":"8","author":"Sumiyoshi","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2017.05.040_bb0240","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","article-title":"Treatment resistant schizophrenia and response to antipsychotics: a review","volume":"133","author":"Suzuki","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0245","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.mp.4000718","article-title":"Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients","volume":"5","author":"Takahashi","year":"2000","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0250","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1476-5381.2011.01638.x","article-title":"Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes","volume":"165","author":"Tanahashi","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.schres.2017.05.040_bb0255","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000054937","article-title":"Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine","volume":"44","author":"Tortorella","year":"2001","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2017.05.040_bb0260","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2004.01.013","article-title":"Effects of typical and atypical antipsychotics on human glycine transporters","volume":"71","author":"Williams","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0265","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.psychres.2010.12.017","article-title":"The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia","volume":"189","author":"Xiong","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2017.05.040_bb0270","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.pnpbp.2009.08.011","article-title":"Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics","volume":"33","author":"Xiu","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.05.040_bb0275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neulet.2013.09.059","article-title":"Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine","volume":"556","author":"Yamamori","year":"2013","journal-title":"Neurosci. Lett."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417303146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417303146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:31:33Z","timestamp":1760297493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417303146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":56,"alternative-id":["S0920996417303146"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.05.040","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.05.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}